Literature DB >> 22239882

Exercise testing in metabolic myopathies.

Mark Tarnopolsky1.   

Abstract

Metabolic myopathies are a group of genetic disorders specifically affecting glucose/glycogen, lipid, and mitochondrial metabolism. The main metabolic myopathies that are evaluated in this article are the mitochondrial myopathies, fatty acid oxidation defects, and glycogen storage disease. This article focuses on the usefulness of exercise in the evaluation of genetic metabolic myopathies.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22239882     DOI： 10.1016/j.pmr.2011.11.011

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN： 1047-9651            Impact factor:   1.784


  5 in total

Review 1.  Perspectives on Exertional Rhabdomyolysis.

Authors:  Eric S Rawson; Priscilla M Clarkson; Mark A Tarnopolsky
Journal:  Sports Med       Date:  2017-03       Impact factor: 11.136

2.  Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.

Authors:  Amel Karaa; Richard Haas; Amy Goldstein; Jerry Vockley; W Douglas Weaver; Bruce H Cohen
Journal:  Neurology       Date:  2018-03-02       Impact factor: 11.800

3.  Association of whole mtDNA, an NADPH G11914A variant, and haplogroups with high physical performance in an elite military troop.

Authors:  C G M Santos; N G Rolim-Filho; C A Domingues; M Dornelas-Ribeiro; J L King; B Budowle; R S Moura-Neto; R Silva
Journal:  Braz J Med Biol Res       Date:  2021-04-26       Impact factor: 2.590

4.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

5.  A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.

Authors:  Amel Karaa; Richard Haas; Amy Goldstein; Jerry Vockley; Bruce H Cohen
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-02-25       Impact factor: 12.910
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.